Physiological changes occurring perinatally and in the first month of life can affect the answer to a pharmacological treatment and the individual response to a drug in terms of efficacy and toxicity is highly variable in the neonatal population. Among potential causes for such variability, differences in drug metabolism may have a great impact. This article aims to review qualitative and quantitative differences in drug metabolizing enzymes in neonates, since both phase I and phase II metabolic pathways are immature at birth and subject to maturational changes in the first period of extrauterine life. Moreover, clinical implications will be discussed.
|Titolo:||Drug metabolizing enzymes in the perinatal and neonatal period: differences in the expression and activity|
|Data di pubblicazione:||2013|
|Appare nelle tipologie:||01.01 Articolo in Rivista|
File in questo prodotto:
|Manuscript drug metabolizing enzymes (Curr Drug Metab 2013).pdf||Documento in Post-print||Accesso ristretto||Administrator Richiedi una copia|